AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
AbbVie (NYSE: ABBV) Delayed: 230.01 +13.52 (6.25%)
Previous Close $216.49    52 Week High $68.12 
Open $221.94    52 Week Low $50.71 
Day High $232.32    P/E 49.89 
Day Low $221.94    EPS $4.61 
Volume 9,912,419